Tempest Therapeutics (TPST) CFO receives 140,000 stock options at $1.64

Rhea-AI Filing Summary

Tempest Therapeutics, Inc. reported that Chief Financial Officer Nicholas Maestas received a grant of employee stock options covering 140,000 shares of common stock at an exercise price of $1.64 per share. These options expire on March 30, 2036 and are held as a direct ownership position.

According to the vesting terms, 25% of the total shares will vest on March 31, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on Maestas’s continued service. Following this grant, he holds 140,000 options in this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Maestas Nicholas

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	140,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 140,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 140,000 options Exercise price: $1.64 per share Underlying shares: 140,000 shares +4 more

7 metrics

Options granted 140,000 options Employee stock option award to CFO Nicholas Maestas

Exercise price $1.64 per share Strike price for underlying common stock

Underlying shares 140,000 shares Common stock underlying the option grant

Grant date March 31, 2026 Transaction date of the option award

Expiration date March 30, 2036 Option term end date

Initial vesting 25% on March 31, 2027 Cliff vesting of first portion of options

Remaining vesting period 36 monthly installments Post-cliff vesting schedule, subject to continued service

Key Terms

Employee Stock Option (right to buy), exercise price, vesting, expiration date, +1 more

5 terms

Employee Stock Option (right to buy) financial

"security_title: "Employee Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "1.6400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"This option shall vest with respect to 25% of the total number of shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-03-30T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maestas Nicholas

(Last) (First) (Middle)

C/O TEMPEST THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 400

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tempest Therapeutics, Inc. [ TPST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.64	03/31/2026		A		140,000		(1)	03/30/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.

	/s/ Nicholas Maestas	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Tempest Therapeutics (TPST) report for Nicholas Maestas?

Tempest Therapeutics reported a grant of employee stock options to CFO Nicholas Maestas for 140,000 shares of common stock. The options are compensation-related, not an open-market purchase or sale, and provide the right to buy shares at a fixed exercise price.

What is the exercise price of the new TPST stock options granted to the CFO?

The options granted to Tempest Therapeutics’ CFO have an exercise price of $1.64 per share. This is the price at which he can buy the company’s common stock under the award, regardless of future market price movements, once the options vest.

How do the TPST stock options granted to the CFO vest over time?

The stock options vest gradually based on continued service. Twenty-five percent of the 140,000 underlying shares vest on March 31, 2027, and the remaining shares vest in 36 equal monthly installments after that date, creating a four-year vesting horizon from the initial cliff vesting.

When do the newly granted Tempest Therapeutics (TPST) options to the CFO expire?

The options granted to the CFO expire on March 30, 2036. After this expiration date, any unexercised portion of the 140,000-share option award can no longer be used to purchase Tempest Therapeutics common stock at the $1.64 exercise price.

Is the TPST Form 4 transaction a stock sale or purchase by the CFO?

The Form 4 transaction is an award of employee stock options, classified as an acquisition, not a market trade. It reflects a compensation grant giving the CFO the right to buy 140,000 shares at $1.64, rather than a direct buy or sell on the open market.